Cardium Therapeutics Inc (NYSEMKT:CXM)’s focus on business opportunity for potential growth, NeoGenomics, Inc (NASDAQ:NEO)

Posted by Kristi Scott May 28, 2013 0 Comment 868 views


Hartford, CT 05/28/2013 (GDPInsider) – In Friday’s trading session, Cardium Therapeutics Inc (NYSEMKT:CXM) dipped by 5.16%. Its opening price of $0.09 was also the intraday high which eventually closed at $0.09 per share. More than 0.305 million shares exchanged hands in the last trading session. This number stood below the average volume of 0.617 million that was measured over a 30-day period.

Cardium Therapeutics Inc (NYSEMKT:CXM) focuses on acquiring and strategically developing businesses or product opportunities that have the potential to address any unmet medical needs. With distribution channels and additional products, it plans to develop MedPodium into a science-based portfolio of easy-to-use neurologics, medicinals, nutraceuticals, metabolics and aesthetics. All these are intended to manage and promote personal health. Generx (alferminogene tadenovec, Ad5FGF-4), is the lead product candidate that has been developed by Cardium Therapeutics Inc (NYSEMKT:CXM)’s  Cardium Biologics unit. It is developed for the treatment of myocardial ischemia caused by coronary heart disease.

Is CXM a solid investment at these levels? Get valuable updates and exclusive insights here.

In Friday’s trading session, NeoGenomics, Inc (NASDAQ:NEO) dipped by 4.76%. Its opening price of $3.68 was the intraday high as well, which eventually headed down to close at $3.58 per share. More than 0.655 million shares exchanged hands in the last trading session. This number stood above the average volume of 0.127 million that was measured over a 30-day period.

NeoGenomics, Inc (NASDAQ:NEO) operates an impressive network of cancer focused testing laboratories. It offers testing services. These include Cytogenetics testing, which is the study of abnormal and normal chromosomes and their connection to disease. It is also involved in fluorescence in-situ hybridization (FISH) testing. This is a cancer genetics branch that is focused on the detection and location of the presence or absence of any genes and specific deoxyribonucleic acid sequences on chromosomes. The company also conducts flow cytometry testing. This is a method of measuring cell population’s characteristics.

How Should Investors Trade NEO Now? Get key and important information right here.

Disclosure:

WallStreetAnalyzed.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit WallStreetAnalyzed.com website, for complete risks and disclosures.


About Kristi Scott

Kristi Scott joined GDP Insider in 2005 as a Wall Street reporter for the Business and Market section. Kristi covers the stock market, financial markets and personal finance. Her awards have come from the National Federation of Professional Writers, the Ohio Newspaper Association, the Cleveland Press Club, the Society of Professional Journalists and Suburban Newspapers of America. Kristi was named SNA's national Journalist of the Year

View all post by Kristi Scott Visit author's website

Write Your Comment